Conference
Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)
Abstract
Abstract
Background: Patients on systemic therapy for cancer are at varying risk for venous thromboembolism (VTE) and its consequences. Thromboprophylaxis is recommended in hospitalized medical and surgical cancer patients, but most VTE occurs in ambulatory cancer patients where risk can be estimated with a validated score. However, the benefit of extended outpatient thromboprophylaxis is uncertain with heparins and has not …
Authors
Khorana AA; Soff GA; Kakkar AK; Vadhan-Raj S; Riess H; Wun T; Streiff MB; Garcia DA; Liebman HA; Belani C
Volume
132
Publisher
American Society of Hematology
Publication Date
November 29, 2018
DOI
10.1182/blood-2018-120738
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971